Kenalog injections for hair loss are a well-established treatment option in UK dermatology, particularly for alopecia areata. Triamcinolone acetonide, the active corticosteroid in Kenalog, is injected directly into affected areas of the scalp to suppress the localised immune response that disrupts hair follicle function. Recognised by both NICE and the British Association of Dermatologists as a first-line approach for patchy alopecia areata, this treatment can support follicular recovery when administered correctly by a qualified clinician. This article explains how the injections work, which conditions may respond, what to expect, and how to access treatment safely in the UK.

How Kenalog Injections Work for Hair Loss

Triamcinolone acetonide is injected intradermally into affected scalp patches at 0.1 mL per site, suppressing the immune response that attacks hair follicles and creating conditions for regrowth. Treatment is repeated every four to six weeks, with response assessed after two to three sessions.

Triamcinolone acetonide (available under the brand name Kenalog) is a long-acting corticosteroid that can be administered by intralesional injection — that is, injected directly into the affected area of the scalp. This localised approach reduces, but does not entirely eliminate, systemic absorption and the associated risks of corticosteroids. Compared with oral steroids, intralesional injections deliver a higher concentration of medication to the target tissue whilst minimising — though not abolishing — broader systemic exposure.

The mechanism of action centres on the drug's potent anti-inflammatory and immunosuppressive properties. In certain types of hair loss, the immune system mistakenly attacks hair follicles, triggering inflammation that disrupts the normal hair growth cycle. Triamcinolone acetonide suppresses this immune response by inhibiting the production of pro-inflammatory cytokines and reducing the activity of immune cells around the follicle, creating a more favourable environment for follicular recovery and regrowth.

Not sure if this is normal? Chat with one of our pharmacists →

In UK clinical practice, the intralesional formulation typically used is triamcinolone acetonide 10 mg/mL (e.g., Kenalog 10 mg/mL injection). It is important to note that the higher-strength 40 mg/mL intramuscular formulation is not appropriate for intralesional scalp use. Depending on the site and extent of involvement, the solution may be diluted to a concentration of 2.5–10 mg/mL. Approximately 0.1 mL is injected intradermally at each site, with injection points spaced roughly 1 cm apart across the affected patches. Treatment is typically repeated every four to six weeks, with response assessed after two to three sessions. If no meaningful regrowth is observed after three to six months of treatment, continuing is unlikely to be beneficial and the approach should be reviewed.

It should be noted that the use of triamcinolone acetonide by intralesional injection for alopecia areata may be considered off-label depending on the specific licensed indication of the product used; clinicians should refer to the relevant Summary of Product Characteristics (SmPC) available on the electronic Medicines Compendium (emc). Kenalog injections do not cure the underlying condition — rather, they help to manage inflammation and support the conditions necessary for regrowth.

Which Types of Hair Loss May Respond to Treatment

Intralesional triamcinolone acetonide is most effective for patchy alopecia areata and is recognised as a first-line option by NICE and the BAD. It does not benefit androgenetic alopecia or telogen effluvium, and is less effective in extensive forms such as alopecia totalis or universalis.

Intralesional triamcinolone acetonide injections are most commonly used in the management of alopecia areata, an autoimmune condition in which the immune system attacks hair follicles, resulting in patchy hair loss on the scalp or elsewhere on the body. The British Association of Dermatologists (BAD) guideline on alopecia areata and NICE Clinical Knowledge Summary (CKS) both recognise intralesional corticosteroids as a first-line treatment option for localised or patchy disease, particularly when patches are limited in number and size and where disease is active.

The treatment may be considered across several presentations:

• Patchy alopecia areata — small to moderate areas of hair loss on the scalp, ideally with fewer patches and earlier active disease

• Alopecia areata of the eyebrows or beard — where localised injection is technically feasible

• Early or active disease — where inflammation is ongoing and follicles remain viable

Intralesional corticosteroids are generally less effective in more extensive forms of the condition, such as alopecia totalis (complete scalp hair loss) or alopecia universalis (total body hair loss), or where the Severity of Alopecia Tool (SALT) score indicates extensive involvement. In these cases, systemic treatments or newer immunological therapies may be more appropriate.

It is equally important to clarify which conditions are unlikely to benefit. Androgenetic alopecia (male or female pattern hair loss) and telogen effluvium (diffuse shedding related to stress or illness) do not respond to intralesional corticosteroids. In scarring alopecias (such as lichen planopilaris or discoid lupus erythematosus), intralesional steroids may help to suppress active inflammation and relieve symptoms, but they cannot regenerate follicles that have already been permanently destroyed by scarring. Treatment in these conditions is therefore aimed at halting progression rather than restoring lost hair.

Use in children requires specialist consideration. The discomfort of repeated injections and the risk–benefit balance mean that alternative approaches are often preferred in younger patients, and any such treatment should be led by a consultant dermatologist.

A thorough clinical assessment — ideally by a consultant dermatologist — is essential before proceeding, as accurate diagnosis directly determines whether this treatment is appropriate.

What to Expect During and After the Procedure

The procedure involves multiple small intradermal injections across affected patches and typically takes 10–30 minutes, with mild swelling or redness resolving within 48 hours. Regrowth, when it occurs, is usually visible four to eight weeks after the first session.

Before the procedure, a clinician will assess the scalp, confirm the diagnosis, and discuss the expected outcomes and potential risks. Photographs of the affected area are often taken to monitor progress over time. Patients should inform their clinician of any existing medical conditions, current medications (including anticoagulants or blood-thinning medicines), or known allergies, particularly to corticosteroids. Treatment should be deferred if there is any active skin infection at or near the injection site.

During the procedure, small amounts of triamcinolone acetonide solution (typically at a concentration of 2.5–10 mg/mL) are injected intradermally at approximately 0.1 mL per site, with sites spaced roughly 1 cm apart across the affected patches. Most patients describe the sensation as a series of brief stinging or pricking feelings. The procedure typically takes between 10 and 30 minutes depending on the size of the area being treated. A topical anaesthetic cream may be applied beforehand to reduce discomfort, though this is not always necessary.

In the hours following the injections, mild swelling, redness, or tenderness at the injection sites is common and usually resolves within 24 to 48 hours. Some patients notice small indentations in the skin (known as atrophy) at injection sites, which is discussed further in the safety section.

Regrowth, when it occurs, is typically observed four to eight weeks after the first treatment session. Hair may initially appear fine or lighter in colour before returning to its normal texture. Multiple treatment sessions are usually required to sustain regrowth, and the response varies considerably between individuals. Clinicians will typically review progress after two to three sessions; if no meaningful response has occurred after three to six months, continuing treatment is unlikely to be of benefit.

Patients should maintain realistic expectations — not everyone will experience significant regrowth, and hair loss may recur after treatment is discontinued.

Possible Side Effects and Safety Considerations

Common localised side effects include skin atrophy, hypopigmentation, and mild bruising; systemic effects such as HPA axis suppression or raised blood glucose are possible with repeated treatment. Patients with diabetes, glaucoma, or adrenal insufficiency should discuss risks carefully with their clinician before proceeding.

Experiencing these side effects? Our pharmacists can help you navigate them →

As with all medical treatments, intralesional triamcinolone acetonide injections carry a risk of side effects. Most are localised and related to the injection technique, though systemic effects can occur — particularly with repeated treatment sessions, larger treatment areas, or higher cumulative doses.

Common localised side effects include:

• Skin atrophy — thinning or depression of the skin at injection sites, which is usually temporary but can occasionally persist

• Hypopigmentation — lightening of the skin around the injection site, more noticeable in individuals with darker skin tones

• Mild pain or bruising — typically short-lived

• Telangiectasia — small visible blood vessels near the surface of the skin

Systemic side effects are less common when injections are administered correctly and at appropriate intervals, but the risk increases with cumulative dose and frequency of treatment. Potential systemic effects include temporary suppression of the hypothalamic-pituitary-adrenal (HPA) axis, raised blood glucose levels, mood or sleep disturbance, menstrual irregularities, hypertension, and, with prolonged or high-dose use, Cushingoid features. Raised intraocular pressure is a recognised class effect of corticosteroids but is rare with intralesional scalp injections; it is more relevant in the context of overall corticosteroid exposure across all routes.

Patients with diabetes, glaucoma, adrenal insufficiency, or skin fragility should discuss these risks carefully with their clinician before proceeding. Caution is also advised in patients taking anticoagulants or medicines that affect bleeding, due to the risk of bruising or haematoma at injection sites. Treatment should not be administered through actively infected skin.

Kenalog injections are not recommended during pregnancy unless the potential benefit clearly outweighs the risk, and caution is advised during breastfeeding. Patients who are pregnant, planning a pregnancy, or breastfeeding should discuss the risks and benefits with their clinician; further information is available from UK Teratology Information Service (UKTIS/bumps) and the relevant product SmPC.

Triamcinolone acetonide is a prescription-only medicine in the UK (MHRA/EMA classification) and must be prescribed and administered by a qualified, registered healthcare professional.

Patients should seek prompt medical advice if they experience signs of infection at injection sites, significant or worsening skin changes, visual disturbances, or unexpected systemic symptoms following treatment.

Suspected side effects should be reported to the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk). Healthcare professionals and patients can both submit reports.

Accessing Kenalog Injections Through NHS or Private Care

NHS access is via GP referral to a consultant dermatologist, though availability varies by Integrated Care Board. Private treatment is available from GMC-registered dermatologists across the UK, typically costing £150–£400 per session.

In the UK, access to intralesional triamcinolone acetonide injections for hair loss depends on the type and severity of the condition, as well as local NHS commissioning policies. For alopecia areata, the NICE Clinical Knowledge Summary (CKS) and the British Association of Dermatologists (BAD) guideline both recognise intralesional corticosteroids as a first-line treatment option for localised disease. NICE does not currently have a dedicated technology appraisal specifically for this intervention.

On the NHS, patients are typically referred to a consultant dermatologist via their GP if hair loss is causing significant distress, if the diagnosis is uncertain, or if initial management has been ineffective. NHS availability of intralesional corticosteroid injections can vary by region due to differences in Integrated Care Board (ICB) funding decisions. Some areas offer this treatment within dermatology outpatient services, whilst others may have more restricted access.

For those who choose to pursue treatment privately, intralesional triamcinolone acetonide injections for hair loss are offered by dermatology clinics across the UK. Costs are approximate and vary widely by region, provider, and the extent of treatment required; as a general guide, fees have typically ranged from £150 to £400 per session, though patients should confirm current pricing directly with their chosen provider. It is essential to ensure that any private provider is a GMC-registered doctor or appropriately qualified prescriber with specialist training in dermatology or hair disorders. Trichologists are not medical doctors unless separately medically qualified, and intralesional corticosteroid injections must be administered by a regulated prescriber with appropriate clinical expertise.

Regardless of the route of access, patients are encouraged to:

• Start with a GP consultation to obtain a formal diagnosis and appropriate referral

• Ask about the clinician's qualifications and experience with intralesional injections

• Discuss realistic outcomes and the likely number of sessions needed before efficacy can be assessed

• Avoid unregulated providers offering corticosteroid injections without a proper medical assessment

Triamcinolone acetonide is a prescription-only medicine in the UK and must never be self-administered or obtained without a valid prescription from a licensed prescriber. Further information on alopecia areata and NHS care pathways is available on the NHS website and through the BAD patient information resources.

Frequently Asked Questions